Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Phase 2

Incyte Corporation